Portal de Periódicos da CAPES

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

2005; Elsevier BV; Volume: 10; Issue: 15 Linguagem: Inglês

10.1016/s1359-6446(05)03512-9

1878-5832

Francesco Hofmann, Carlos Garcı́a-Echeverrı́a,

PI3K/AKT/mTOR signaling in cancer

Clear links between cancer and cellular signaling triggered by the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) and its cognate ligands (IGF-I and IGF-II) have been reported throughout the past two decades. Experimental results suggest that the pharmaceutical targeting of this signaling pathway could be beneficial for the treatment of cancer. Here, more recent advances towards potentially clinically viable strategies to interfere with the function of IGF-IR will be discussed.